Venture Science

Alex Bangash, the founder and managing partner, leads investment decisions. The firm applies a quantitative decision framework where internal data models score opportunities before investment committee review. Bangash's background spans engineering and data science, which informs the firm's systematic approach to early-stage deal selection.

The firm relies on proprietary data pipelines and quantitative screening rather than traditional venture networks. Internal software scans public and licensed datasets for early signals — founding team composition, technology velocity, and market inflection points — generating a funnel that reduces dependency on warm introductions or demo-day visibility.

Venture Science operates as a traditional venture capital asset manager raising committed capital from external limited partners. It is not a family office. The firm manages pooled fund vehicles with a mandate concentrated on seed and Series A investments in software and science-driven startups.

The firm focuses on direct primary investments in startups. There is no public record of Venture Science making fund commitments to other venture firms or participating in secondary transactions. The strategy is to own positions directly in companies the firm's quantitative models select.

The firm targets seed and Series A stages, with initial check sizes in the hundreds of thousands to low millions. Venture Science reserves capital for follow-on investments through early growth rounds, maintaining ownership in companies that meet quantitative performance thresholds.

Venture Science applies a scoring architecture that links every investment decision to a model output, creating an auditable decision trail. In 2022, the firm published a study analyzing founder-attribute correlations with exit outcomes across 2,000 seed-stage companies — a level of methodological transparency uncommon among early-stage managers.

The firm does not publicly list excluded sectors, but its stated focus areas — enterprise software, applied AI, digital health, fintech, and climate tech — suggest limited appetite for capital-intensive industries like hardware, medical devices requiring FDA trials, or consumer brands where quantitative signals are less predictive.